Novel freeze-drying process of landiolol hydrochloride for injection
By introducing prefreezing and annealing steps in the lyophilization process of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of lyophilization of Security.
Patent Information
- Application Number
- CN202410710468.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-03
- Publication Date
- 2024-11-29
AI Technical Summary
The existing lyophilized lyophilized lyophilized lyophilized process has high impurities and a lot of moisture, which leads to unstable product quality and is difficult to meet the requirements of high-quality injection drugs.
The prefreezing and annealing steps are introduced in the lyophilization process, and sublimation drying and desorption drying are performed by controlling the shelf temperature and vacuum of the freeze-dryer, and at least one annealing operation is added to reduce impurity content and moisture.
It significantly reduces the impurity content and moisture, improves the quality stability of the preparation, makes lycyrrol hydrochloride for injection more suitable for clinical applications, and improves the solubility and safety of the drug.
Smart Images

Figure BDA0004873859260000044 
Figure BDA0004873859260000045 
Figure BDA0004873859260000051
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a novel freeze-drying process of landiolol hydrochloride for injection. Background Art
[0002] Landiolol hydrochloride is an ultra-short-acting, highly selective β-receptor blocker developed by Ono Pharmaceutical Co., Ltd. of Japan. It was first launched in Japan in September 2002 for the treatment of tachycardia-induced arrhythmias during surgery (atrial fibrillation, atrial flutter and solid tachycardia). Its selectivity for β1 receptors is stronger than similar drugs (esmolol and propranolol). As a β-blocker, landiolol hydrochloride is different from previous β-blockers in structure in that the amino side chain of propanol and its para-side chain structure are changed, the amino group is a morpholinocarbonylamide group, and the ester-forming alcohol is an S-configured 1,2-ketal glycerol alcohol; in terms of pharmacological activity, the two most prominent points are: landiol hydrochloride has high selectivity for β1-adrenergic receptors and a very short half-life. The relationship between these two structural changes and its superiority in pharmacological activity is worth studying, and the research results will be able to better guide the design and development of short-acting, highly selective β-blockers.
[0003] Compared with the similar drug esmolol, landiolol hydrochloride has the following advantages: 1. Higher cardiac selectivity: In vitro studies have shown that the β1 / β2 value of landiolol is 255, while that of esmolol is 33, and the cardiac selectivity is about 8 times that of esmolol; 2. Faster onset: Junichi et al.'s experiments have shown that intravenous injection of 3 mg / kg of landiolol can produce a heart rate slowing effect within 30 seconds, while 5 mg / kg of esmolol can only take effect within 2 minutes; 3. Shorter duration of action: The duration of landiolol's heart rate slowing effect is about 4 minutes, while esmolol is about 9 minutes; 4. Fewer side effects: Data show that the main adverse reaction of esmolol is hypotension, with an incidence of hypotension of 63% during injection and an incidence of persistent hypotension of 80% after stopping the drug. The incidence of adverse reactions of landiolol is 15.6%, and the incidence of hypotension is 11.7%, which is safer than esmolol. Esmolol is the first ultra-short-acting, selective second-generation B1-receptor blocker used clinically. Landiolol hydrochloride is a new compound obtained by structural improvement on the basis of esmolol. In terms of both efficacy and safety, landiolol has more advantages than esmolol and can be used as a replacement product for esmolol.
[0004] Overseas listed products It is a sterile lyophilized powder injection, and mannitol is used as a lyophilization protective agent and sodium hydroxide is used as a pH regulator in the prescription. Patent CN101732319A in the prior art discloses a pharmaceutical composition for injection containing the active ingredient of landiolol hydrochloride and a preparation method thereof. The sample prepared by the freeze-drying process in the patent has large impurities and high moisture content. Patent CN102232330A discloses a landiolol hydrochloride pharmaceutical composition and a preparation method thereof. The sample prepared by the freeze-drying process in the patent has large impurities. Patent CN106265539A discloses a landiolol hydrochloride freeze-dried powder injection and a preparation process thereof. The sample prepared by the freeze-drying process in the patent has large impurities and high moisture content.
[0005] In summary, existing products and technologies cannot fully realize the production of stable landiolol hydrochloride injection products with low impurity content. In order to provide a product with stable quality, the inventors have found through a large number of experiments that a freeze-dried sample with stable quality, low impurity content and low water content can be produced through continuous optimization of the preparation process. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides a lyophilized powder injection of landiolol hydrochloride with good solubility and safe efficacy and a preparation process thereof.
[0007] The object of the present invention is to provide a freeze-drying process for preparing landiolol hydrochloride for injection. The process is to study the pre-freezing process of the marketed product without changing the prescription of the marketed product, add an annealing operation, and then obtain a preparation product. Compared with the ordinary freeze-drying process, the obtained preparation product has reduced impurities and stable quality.
[0008] In the landiolol hydrochloride for injection of the present invention, the excipient is mannitol, and the pH regulator is sodium hydroxide.
[0009] The preparation process of landiolol hydrochloride for injection of the present invention comprises the following specific steps: dissolving mannitol with part of water for injection, cooling to below 25°C, adding landiolol hydrochloride and stirring to dissolve, adjusting the pH value with a pH regulator, replenishing water for injection to the full amount, filtering, filling, freeze-drying and capping.
[0010] More specifically, the present invention provides a freeze-drying process for preparing landiolol hydrochloride for injection, the process comprising pre-freezing, sublimation drying, and desorption drying steps, characterized in that after pre-freezing, at least one annealing step is included.
[0011] Preferably, the annealing step comprises raising the shelf temperature to -20 to 10°C, preferably -10 to 10°C, preferably -10 to 0°C, more specifically, the annealing step comprises raising the shelf temperature to -10, -9, -8, -7, -6, -5, -4, -3, -2, -1 or 0°C.
[0012] Preferably, the annealing step comprises keeping warm for 0.5 to 12 hours, preferably 0.5 to 6 hours, more preferably 1 to 3 hours, and more specifically, the annealing step comprises keeping warm for 1, 2 or 3 hours.
[0013] Preferably, the annealing step may further include cooling the shelf temperature to below -40°C, preferably, keeping warm for 0.5 to 12 hours after cooling, preferably 0.5 to 6 hours, more preferably 1 to 3 hours, more specifically, keeping warm for 1, 2 or 3 hours after cooling.
[0014] Preferably, the process comprises 1, 2 or 3 annealing steps.
[0015] Preferably, the pre-freezing step comprises placing the half-stoppered bottle of the dispensed medicine solution into a freeze dryer, and lowering the shelf temperature of the freeze dryer to below -40°C. Preferably, the cooling rate is 0.5°C / min to 2°C / min, preferably 0.75°C / min to 1.25°C / min, and more specifically the cooling rate is 0.5, 0.75, 1, or 1.25°C / min. Preferably, the pre-freezing step comprises keeping warm for 0.5 to 12 hours, preferably 0.5 to 6 hours, and more preferably 1 to 3 hours.
[0016] Preferably, the sublimation drying step includes evacuating, and when the vacuum degree reaches below 20 to 50 Pa, the temperature is increased. Preferably, the vacuum degree reaches below 20, 30, 40 or 50 Pa. Preferably, the shelf temperature is increased to -20 to 10°C, preferably -15 to 10°C, preferably -10 to 5°C. Preferably, the shelf is kept warm for 4 to 24 hours, preferably 6 to 18 hours, and more preferably 8 to 12 hours.
[0017] Preferably, the desorption drying step comprises raising the shelf temperature to 25°C to 45°C, preferably 35°C to 40°C, and preferably, keeping the shelf warm for 0.5 to 12 hours, preferably 1 to 6 hours, and more preferably 2 to 4 hours.
[0018] Preferably, the process further comprises plugging, breaking the vacuum, and discharging the material to obtain the finished product of landiolol hydrochloride for injection.
[0019] Preferably, the present application provides a freeze-drying process for preparing landiolol hydrochloride for injection, the process comprising:
[0020] A. Pre-freezing: Place the half-stoppered bottles of the dispensed liquid into the freeze dryer, and lower the shelf temperature of the freeze dryer to below -40°C at a rate of 0.75-1°C per minute. When the product temperature drops below -40°C, keep it warm for 1-3 hours;
[0021] B. Annealing: Raise the shelf temperature to -10 to 0°C and keep it warm for 1 to 3 hours; then lower the shelf temperature to below -40°C and keep it warm for 1 to 3 hours;
[0022] C. Sublimation drying: Start vacuuming. When the vacuum degree reaches below 20-50Pa, start heating up the shelf to -10℃~5℃ and keep it for 8-12 hours.
[0023] D. Desorption and drying: Raise the shelf temperature to 35℃~40℃ and keep warm for 2~4 hours;
[0024] E. Press the stopper, break the vacuum, and discharge the material to obtain the finished product of landiolol hydrochloride for injection.
[0025] The present invention also provides landiolol hydrochloride for injection prepared by the freeze-drying process described in any one of the above items.
[0026] The advantages of the preparation of the present invention are: the drug preparation is stable, has good solubility in water, is convenient for storage, transportation, carrying and clinical application, and is safe and effective for clinical use.
[0027] In combination with the characteristics of this product, the freeze-drying process has been studied in detail and greatly improved to solve the defects in the existing technology. Through research, it is found that adding annealing operation in the pre-freezing process can not only make the appearance of the finished product better, but also significantly reduce the related substances of the obtained powder injection, ensuring the safety of clinical medication. DETAILED DESCRIPTION
[0028] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0029] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0030] The impurity structural formula involved in the embodiment of the present invention is as follows:
[0031] The structural formula of impurity A is: (Molecular formula: C 22 H 35 N3O8; molecular weight: 469.5).
[0032] The structural formula of impurity B is: (Molecular formula: C 19 H 29 N3O6; molecular weight: 395.5).
[0033] The structural formula of impurity F is: (Molecular formula: C 21 H 30 N2O7; molecular weight: 422.5).
[0034] The detection method of the related substances involved in the present invention is as follows:
[0035] Take an appropriate amount of this product, weigh it accurately, dissolve it in water and dilute it to make a solution containing about 0.5 mg of landiolol hydrochloride per 1 ml as the test solution; determine it according to the high performance liquid chromatography method, use octadecylsilane bonded silica gel as the filler; use 10mmol / L phosphate buffer as mobile phase A, acetonitrile as mobile phase B, and perform gradient elution according to the table below; the flow rate is 1.0ml per minute; the detection wavelength is 220nm; the column temperature is 35℃. Accurately measure 20μl of the test solution, inject it into the liquid chromatograph, and record the chromatogram. Calculate by area normalization method.
[0036]
[0037] Example
[0038] Take 5g of landiolol hydrochloride, dissolve it in 180ml of water for injection, add 5g of mannitol, stir to dissolve, slowly drop 1% (w / w) sodium hydroxide solution, adjust the pH value to 6.0, add water for injection to 200ml volume. Pack 2ml / bottle, half-stopper, freeze-dry using the following different freeze-drying processes, see the table below for details:
[0039] Table 1 Freeze-drying procedure
[0040]
[0041]
[0042] The samples were freeze-dried according to different freeze-drying procedures, plugged and capped. After the 0-day samples were tested for moisture and related substances, they were placed at high temperatures of 40°C and 60°C to observe the changes in related substances. At the same time, they were compared with the Japanese marketed products. The results are as follows:
[0043] Table 2 0-day freeze-dried sample detection
[0044] Example 1 2 3 4 5 6 7 8 9 10 Moisture 1.04% 0.48% 0.38% 0.35% 0.42% 0.45% 0.80% 0.49% 0.50% 0.36% Impurity A 0.20% 0.06% 0.08% 0.08% 0.10% 0.08% 0.06% 0.09% 0.08% 0.07% Impurity B 0.08% 0.03% 0.04% 0.02% 0.02% 0.03% 0.02% 0.02% 0.03% 0.02% Impurity F 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% Total Miscellaneous 0.30% 0.11% 0.14% 0.12% 0.14% 0.13% 0.10% 0.13% 0.13% 0.11%
[0045] Table 3 40℃30-day freeze-dried sample test
[0046] Example 1 2 3 4 5 6 7 8 9 10 Impurity A 0.20% 0.08% 0.09% 0.08% 0.09% 0.06% 0.06% 0.09% 0.08% 0.09% Impurity B 0.17% 0.05% 0.05% 0.04% 0.06% 0.04% 0.03% 0.04% 0.03% 0.03% Impurity F 0.02% 0.02% 0.02% 0.02% 0.02% 0.03% 0.03% 0.02% 0.02% 0.01% Unknown total 0.23% 0.06% 0.05% 0.05% 0.06% 0.04% 0.06% 0.04% 0.05% 0.05% Total Miscellaneous 0.62% 0.21% 0.21% 0.19% 0.23% 0.17% 0.18% 0.19% 0.18% 0.18%
[0047] Table 4 60℃30-day freeze-dried sample test
[0048] Example 1 2 3 4 5 6 7 8 9 10 Impurity A 0.23% 0.08% 0.09% 0.08% 0.09% 0.06% 0.05% 0.09% 0.08% 0.09% Impurity B 0.19% 0.05% 0.06% 0.04% 0.07% 0.04% 0.06% 0.05% 0.03% 0.05% Impurity F 0.02% 0.22% 0.23% 0.21% 0.19% 0.19% 0.19% 0.18% 0.20% 0.19% Unknown total 0.80% 0.28% 0.22% 0.24% 0.30% 0.26% 0.32% 0.24% 0.28% 0.25% Total Miscellaneous 1.24% 0.63% 0.60% 0.57% 0.65% 0.55% 0.62% 0.56% 0.59% 0.58%
[0049] Table 5 Factors affecting the Japanese original research and development reference
[0050]
[0051]
[0052] From the results, the moisture content of the freeze-dried sample of Example 1 prepared by the non-annealing process at 0 days is higher than that of the samples of Examples 2 to 10 prepared by the annealing process, and the impurity A and total impurities are significantly higher than those of the samples prepared by the annealing process. After the high temperature influence factor is released, the impurity B, the largest unknown single impurity, and the total impurity growth rate of the sample of Example 1 at 40°C for 30 days are faster than those of the samples of Examples 2 to 10, and the impurity B, impurity F, and total impurity growth rate of the sample of Example 1 at 60°C for 30 days are faster than those of the samples of Examples 2 to 10. In addition, the applicant unexpectedly found that the impurity A, impurity B, and total impurities of the samples of Examples 2 to 10 are smaller than those of the original Japanese marketed products.
[0053] Furthermore, according to the above-mentioned embodiment, different freeze-drying process parameters were investigated with an annealing temperature of -6°C and annealing times of 1 time.
[0054] Take 5g of landiolol hydrochloride, dissolve it in 180ml of water for injection, add 5g of mannitol, and stir to dissolve it. Slowly drop 1% (w / w) sodium hydroxide solution, adjust the pH value to 6.0, and add water for injection to a volume of 200ml. Pack 2ml / bottle, half-stopper, and freeze-dry using the following different freeze-drying processes, see the table below for details:
[0055] Table 6 Freeze-drying procedure
[0056]
[0057] The samples were freeze-dried with different freeze-drying procedures at an annealing temperature of -6°C, plugged and capped, and the results of the 0-day sample testing for moisture and related substances were as follows:
[0058] Table 7 0-day freeze-dried sample detection
[0059]
[0060]
[0061] From the results, under the condition of annealing temperature of -6℃, different pre-freezing time, sublimation drying temperature, sublimation drying vacuum degree and analytical drying temperature, there was no significant difference in the moisture content and related substances of the 0-day freeze-dried samples.
Claims
1. A freeze-drying process for preparing landiolol hydrochloride for injection, the process comprising the steps of pre-freezing, sublimation drying, and desorption drying, characterized in that: After pre-freezing, at least one annealing step is included.
2. The freeze-drying process according to claim 1, characterized in that The annealing step comprises raising the shelf temperature to -20 to 10°C, preferably -10 to 10°C, preferably -10 to 0°C, more specifically, the annealing step comprises raising the shelf temperature to -10, -9, -8, -7, -6, -5, -4, -3, -2, -1 or 0°C; Preferably, the annealing step comprises keeping warm for 0.5 to 12 hours, preferably 0.5 to 6 hours, more preferably 1 to 3 hours, and more specifically, the annealing step comprises keeping warm for 1, 2 or 3 hours.
3. The freeze-drying process according to claim 2, characterized in that: The annealing step may further include cooling the shelf temperature to below -40°C, preferably, keeping the temperature for 0.5 to 12 hours, preferably 0.5 to 6 hours, more preferably 1 to 3 hours, more specifically, keeping the temperature for 1, 2 or 3 hours after cooling.
4. The freeze-drying process according to claim 1, characterized in that: The process includes 1, 2 or 3 annealing steps.
5. The freeze-drying process according to claim 1, characterized in that: The pre-freezing step comprises placing the half-stoppered bottle of the sub-packaged liquid medicine into a freeze dryer, and lowering the shelf temperature of the freeze dryer to below -40°C. Preferably, the cooling rate is 0.5°C / min to 2°C / min, preferably 0.75°C / min to 1.25°C / min. Preferably, the pre-freezing step comprises keeping warm for 0.5 to 12 hours, preferably 0.5 to 6 hours, and more preferably 1 to 3 hours.
6. The freeze-drying process according to claim 1, characterized in that: The sublimation drying step includes evacuating the air, and when the vacuum degree reaches below 20 to 50 Pa, the temperature is increased. Preferably, the vacuum degree reaches below 20, 30, 40 or 50 Pa. Preferably, the shelf temperature is increased to -20 to 10°C, preferably -15 to 10°C, preferably -10 to 5°C. Preferably, the shelf is kept warm for 4 to 24 hours, preferably 6 to 18 hours, and more preferably 8 to 12 hours.
7. The freeze-drying process according to claim 1, characterized in that: The desorption drying step comprises raising the shelf temperature to 25°C to 45°C, preferably 35°C to 40°C, and preferably, keeping the shelf warm for 0.5 to 12 hours, preferably 1 to 6 hours, and more preferably 2 to 4 hours.
8. The freeze-drying process according to claim 1, characterized in that: The process further comprises plugging, breaking the vacuum, and discharging the material to obtain the finished product of landiolol hydrochloride for injection.
9. The freeze-drying process according to claim 1, characterized in that: The process comprises: A. Pre-freezing: Place the half-stoppered bottles of the dispensed liquid into the freeze dryer, and lower the shelf temperature of the freeze dryer to below -40°C at a rate of 0.75-1°C per minute. When the product temperature drops below -40°C, keep it warm for 1-3 hours; B. Annealing: Raise the shelf temperature to -10 to 0°C and keep it warm for 1 to 3 hours; then lower the shelf temperature to below -40°C and keep it warm for 1 to 3 hours; C. Sublimation drying: Start vacuuming. When the vacuum degree reaches below 20-50Pa, start heating up the shelf to -10℃~5℃ and keep it for 8-12 hours. D. Desorption and drying: Raise the shelf temperature to 35℃~40℃ and keep warm for 2~4 hours; E. Press the stopper, break the vacuum, and discharge the material to obtain the finished product of landiolol hydrochloride for injection.
10. Landiolol hydrochloride for injection prepared by the freeze-drying process according to any one of claims 1 to 9.
Citation Information
Patent Citations
Landiolol hydrochloride active ingredient-containing medicinal composition for injection and preparation method thereof
CN101732319A
Garlic harvester
CN102232330A
Hydrochloric acid landiolol freeze-dried powder injection and preparation process thereof
CN106265539A
Cited By
Esmolol hydrochloride freeze-dried powder, preparation method and application thereof
CN119732912A
